DHR
NYSE · Life Sciences Tools & Services
Danaher Corp
$161.91
-2.63 (-1.60%)
Financial Highlights (FY 2026)
Revenue
24.33B
Net Income
3.58B
Gross Margin
59.2%
Profit Margin
14.7%
Rev Growth
-2.7%
D/E Ratio
0.35
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 59.2% | 59.2% | 33.1% | 33.1% |
| Operating Margin | 19.2% | 17.3% | 22.8% | 20.7% |
| Profit Margin | 14.7% | 14.0% | 16.1% | 14.5% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 24.33B | 24.99B | 64.73B | 56.82B |
| Gross Profit | 14.41B | 14.80B | 21.40B | 18.79B |
| Operating Income | 4.66B | 4.31B | 14.74B | 11.75B |
| Net Income | 3.58B | 3.31B | 10.42B | 8.26B |
| Gross Margin | 59.2% | 59.2% | 33.1% | 33.1% |
| Operating Margin | 19.2% | 17.3% | 22.8% | 20.7% |
| Profit Margin | 14.7% | 14.0% | 16.1% | 14.5% |
| Rev Growth | -2.7% | -2.7% | +18.7% | +12.4% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 14.90B | 14.90B | 69.79B | 63.61B |
| Total Equity | 42.50B | 42.50B | 119.38B | 109.88B |
| D/E Ratio | 0.35 | 0.35 | 0.58 | 0.58 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | 5.41B | 5.28B | 20.74B | 18.10B |
| Free Cash Flow | — | — | 7.59B | 7.26B |